Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

azilsartan

azilsartan
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Edarbi TABLET, ORAL 40 mg, 80 mg    
VIEW MORE Angiotensin II Receptor Antagonists
CLASS
243208
Comments:

Edarbi is approved for sample use in HH Endocrinology and Diabetes Clinics.

ORDERED FORMULATION

FORMULARY INTERCHANGE

NOTES

azilsartan (EDARBI)*

  • 40 mg

azilsartan (EDARBI)*

  • 80 mg

losartan (COZAAR)

  • 100 mg

valsartan (Diovan)

  • 320 mg

Note that 80 mg dose is converted to valsartan

*If ordered twice daily, convert total daily dose to losartan equivalent and give ONCE DAILY; for dosage conversions higher than listed above, contact the physician and discuss dosing (generally, there is little additional benefit from higher doses than those specified)

Reviewed: May 24, 2011

Last updated: Jan. 17, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved